Insider buying last 90 days
No open-market insider purchases were filed for APGE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every APGE insider filing, plotted on the chart in Gekko.Open APGE in Gekko
No recent trading data for APGE. The last close Gekko holds is Sep 2, 2026, so the figures on this page may be out of date.
NASDAQ: APGE
Apogee Therapeutics (APGE) Stock Analysis & Forecast
Sep 2 close
$135.07−0.01 (0.0%)
Gekko Brief
Apogee Therapeutics closed at $135.07 on 2 September 2026, 0% on the day. The price sits above both the 50-day ($134.13) and 200-day ($91.97) moving averages, inside a 52-week range of $35.39 to $135.09. The GekkoIndex reads 41.4, in the Distribution zone, down 4.4 points over five sessions. Gekko Fair Value is $134.62, so the price is 0.3% above it.
The next earnings report is due on 9 November 2026, 41 days away (before open). Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 5.5% across the report. Seasonally, the next 20 trading days from this point averaged +2.2% over the last 3 years, rising in 1 of them.
15 firms rate the stock: 3 buy, 12 hold and 0 sell, with a consensus target of $134.62. A typical daily move is about 0.1%, and a typical 20-day move about 12.6%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (gekkoindex).
Generated Sep 29, 2026 from the data above.
Apogee Therapeutics price vs fair value
Close $135.07200-day averageGekko Fair Value $134.62
Apogee Therapeutics quick facts
- Market cap
- $8.36B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.34
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.33
- Volume
- 5.14M avg 1.38M
- 1-year return
- +256.8%
- Typical daily move
- ±0.1%
- Typical 20-day move
- ±12.6%
- 50-day average
- $134.13
- 200-day average
- $91.97
- Next earnings
- Nov 9 before open
- Shares outstanding
- 62.20M
Apogee Therapeutics swing-trade checklist
Apogee Therapeutics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $135.07 is above the 50-day ($134.13) and 200-day ($91.97) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
41.4, Distribution
Reading 41.4 is in the Distribution zone.
See the GekkoIndex - Fair valuemixed
0.3% above
Price is within 5% of Gekko Fair Value (0.3% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+2.2% on average
From this point in the calendar, the next 20 trading days averaged +2.2% over 3 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Apogee Therapeutics stock chart and price history
Apogee Therapeutics closed at $135.07 on Sep 2, 2026, +256.8% over the past year, inside a 52-week range of $35.39 to $135.09.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.7%
- 3 months
- +60.4%
- 6 months
- +86.8%
- 1 year
- +256.8%
The full APGE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open APGE in Gekko
Follow Apogee Therapeutics through every session
Put APGE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track APGE in GekkoFree for 7 days. No credit card required.
About Apogee Therapeutics
Apogee Therapeutics develops biologic drug candidates aimed at treating inflammatory and immunological conditions, including atopic dermatitis and chronic obstructive pulmonary disease. The company works through a subsidiary and is best known for two programs in particular: APG777, a subcutaneous monoclonal antibody built for extended half-life to address atopic dermatitis, and APG808, a similarly designed antibody targeting COPD.
Beyond these lead candidates, Apogee Therapeutics is advancing earlier-stage work, including APG990, another extended half-life subcutaneous antibody for atopic dermatitis, and APG222, a program built around extended half-life subcutaneous antibodies also directed at that condition. Its efforts center on engineering antibody therapies that require less frequent dosing while addressing chronic inflammatory disease.
Apogee Therapeutics was established in 2022 and is headquartered in Waltham, Massachusetts. Its shares are listed on the NASDAQ under the ticker APGE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- apogeetherapeutics.com
Apogee Therapeutics GekkoIndex: the smart money zone
Apogee Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 41.4, in the Distribution zone, down 4.4 points over five sessions.
41.4Distribution
Down 4.4 points over five sessions, from the Neutral zone.
Reading for Sep 2, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 32 | +5.4% | +13.7% |
| Accumulation | 167 | +1.2% | +3.8% |
| Neutral | 398 | +1.5% | +7.8% |
| Distribution (current zone) | 45 | +1.4% | +1.2% |
| Selling | 14 | +3.0% | −0.9% |
Average APGE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the APGE price, zone by zone.Track APGE in Gekko
Is Apogee Therapeutics stock overvalued? Gekko Fair Value
Apogee Therapeutics trades 0.3% above Gekko Fair Value of $134.62, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Apogee Therapeutics shares are worth, recalculated every trading day.
$134.62
Gekko Fair Value, Sep 12, 2026
0.3% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open APGE in Gekko
Apogee Therapeutics insider and Congress trading
No open-market insider purchases were filed for Apogee Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in APGE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for APGE, plotted on the chart in Gekko.Open APGE in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds APGE.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Apogee Therapeutics earnings: next date and track record
Apogee Therapeutics reports on Nov 9, 2026, before the open (41 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 41 days away
- EPS estimate
- −$1.14
3 of 8reports beat the EPS estimate
±5.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$1.14 est −$1.10 | — est $10.00M | −0.1% |
| May 11, 2026 | −$1.06 est −$1.13 | — | −0.1% |
| Mar 2, 2026 | −$1.03 est −$0.62 | — | −2.1% |
| Nov 10, 2025 | −$1.11 est −$1.12 | — | +15.1% |
| Aug 11, 2025 | −$1.13 est −$1.03 | — | +3.7% |
| May 12, 2025 | −$0.95 est −$1.19 | — | +6.6% |
| Mar 3, 2025 | −$1.18 est −$0.62 | — | −3.4% |
| Nov 12, 2024 | −$0.86 est −$0.74 | — | −12.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Apogee Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Apogee Therapeutics is $134.62, −0.3% from the last close, from 15 firms rating the stock in the last 90 days.
$134.62consensus 12-month target, −0.3% from the last close
Now $135.07Avg $134.62
Low $89High $137
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 13 | Citi | $135 | −0.1% |
| Aug 13 | Truist Financial | $135 | −0.1% |
| Aug 11 | Canaccord Genuity | $135.11 | 0.0% |
| Aug 11 | Wedbush | $135 | −0.1% |
| Aug 10 | RBC Capital | $135 | −0.1% |
+1.2%average 20-day move after past Distribution readings
+2.2%average move over the next 20 trading days in the last 3 years
±0.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Apogee Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Apogee Therapeutics averaged +2.2% across the last 3 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 1 of 3 |
| Next 10 trading days | +11.2% | 2 of 3 |
| Next 15 trading days | +14.8% | 2 of 3 |
| Next 20 trading days | +2.2% | 1 of 3 |
| Next 30 trading days | +9.0% | 2 of 3 |
For scale, APGE’s typical 20-trading-day move in either direction is about 12.6%.
Apogee Therapeutics market cap and key statistics
Apogee Therapeutics’s market cap is $8.36B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $8.36B
- EPS, TTM
- −$4.34
- Gekko Fair Value
- $134.62
Trading
- Volume
- 5.14M
- Avg volume, 20 days
- 1.38M
- 52-week high
- $135.09
- 52-week low
- $35.39
- Shares outstanding
- 62.20M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -32.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.33
- Typical daily move
- ±0.1%
- Typical 20-day move
- ±12.6%
Apogee Therapeutics stock news this week
3 headlines about Apogee Therapeutics from the past week, newest first, each linking to the publisher.
- AbbVie Completes Acquisition of Apogee TherapeuticsPRNewsWire, Sep 3
- Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from S&P TMI Indexmarketscreener.com, Sep 2
- Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry Indexmarketscreener.com, Sep 2
Apogee Therapeutics peers
Apogee Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Apogee Therapeutics stock FAQ
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $8.36B at the Sep 2, 2026 close of $135.07, with 62.20M shares outstanding.
What is the Apogee Therapeutics stock forecast?
The consensus analyst 12-month price target for Apogee Therapeutics is $134.62, −0.3% from the last close. Of the 15 firms that rated the stock in the last 90 days, 3 rate it a buy, 12 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Apogee Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Apogee Therapeutics is about fair value: the Sep 2, 2026 close of $135.07 is 0.3% above Gekko Fair Value of $134.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Apogee Therapeutics report earnings next?
Apogee Therapeutics is expected to report on Nov 9, 2026, before the market opens (41 days away). Analysts expect earnings of −$1.14 per share. Apogee Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 5.5% on average across the report.
What is Apogee Therapeutics’s 52-week high and low?
Apogee Therapeutics’s 52-week high is $135.09 and its 52-week low is $35.39; it closed at $135.07 on Sep 2, 2026, +256.8% over the past year.
Is Apogee Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (fair value and seasonality) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Apogee Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.